BetterLife Pharma CEO Ahmad Doroudian joined Steve Darling from Proactive to share news the company has obtained additional positive data confirming the anti-depressant activity of its lead compound 2-bromo-LSD in preclinical models of depression. Doroudian telling Proactive the current study evaluated the anti-depressant activity of BETR-001 on depressive-like behavior of mice in a forced swim test. The amount of time mice spend immobile was significantly reduced 24 hours after treatment with single dose of BETR-001.
BetterLife Pharma able to demonstrate BETR-001 Anti-Depressant activity in Preclinical Models
